Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.
about
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersImpact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyPrognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisCabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinibRANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIsDevelopment and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinibOpposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancerClinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma.Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions.Management of painful pelvic bone metastasis of renal cell carcinoma using embolization, radio-frequency ablation, and cementoplasty: a prospective evaluation of efficacy and safety.Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis.Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.Spinal metastasectomy of renal cell carcinoma: A 16-year single center experience with a minimum 3-year follow-up.Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy.Prognostic significance of intensive local therapy to bone lesions in renal cell carcinoma patients with bone metastasis.Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case reportOutcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.The use of sunitinib in renal cell carcinoma: where are we now?Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.Skeletal metastasis in renal cell carcinoma: A review.Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
P2860
Q28082793-4E473CC6-3946-43D6-8815-68949460D799Q34007924-CFC37C6D-C5F7-468C-8AB5-BC8A998F5DC7Q34090594-33D56BCE-9CEB-465C-9F0D-680B86D60418Q34661359-888633E6-3568-46EB-8811-DFD7381C5EAAQ34854941-4F0D8B04-47F0-43E2-9F13-FA53ACF88829Q35083485-AB52FC95-49AD-4C5D-8644-B9574EFBEE24Q35956248-DDFA461D-AD8B-42FB-85C3-41C2145D3DB6Q35985736-8769EF55-BE62-4AC0-AA8E-54D5A0B2F3FBQ36281483-9BA86470-E1FF-42E0-8AF4-C0B816F38A4DQ36385639-7265B1D7-CA19-4E93-8FA7-737D1171C29AQ36522330-20A6C4AD-3944-4D99-A2E1-D4C46E370C8FQ36663566-8C2E85D7-2290-44AE-9740-2EF1A123F74BQ36750660-69E373E0-3DA2-4485-A198-291E9261089BQ37040692-96F1F457-2BA9-41AF-8AA5-1D7BE0242CE4Q37295831-A63427A8-F611-4DBF-9670-6AFFF6B8DDD1Q37520452-3335E629-DFCC-4F05-A830-CE14258CA5C3Q37616807-3BCC6272-7A8A-4325-9FE3-A1D515A5FF12Q38094612-AE32015B-DB4F-4C65-8BF2-967E79134E01Q38144897-8D0FCD52-17AB-46C4-9AB4-6586C5DAFF92Q38148971-729FCD4E-52B5-4BBB-92E0-8979174405ABQ38171327-B67912A9-B6AD-47E0-8D93-0A796F999209Q38196855-BBD339A0-F321-47F8-85FE-0DE1063EBA28Q38430335-9C02E4A9-013E-4CA3-A2E7-2B41A0F3E089Q38543085-B64A5678-5FF7-4FDD-B713-0A38EFBD8EB3Q38786760-7802BC8B-2664-4065-8EBB-2057EC9AE806Q38990710-68D4B1AD-66BD-4FC9-8567-25696645873DQ39601152-9FAEF3AF-D656-48AB-BD04-C61AC1E0602AQ40761584-F784403F-AA5F-441F-B313-EE1EDB14FD97Q40929096-E5AAB8C2-19E2-4BD4-9F8E-ACD5F9EC3D82Q41111225-F0BA9DCC-EF2F-4A85-9122-4EA2D3528E49Q41145898-58A34360-F6AE-4A61-8511-5170EC26ED7CQ41780002-F6FF50EB-B41A-4190-8EC1-3F71B626308FQ42102361-34D528AF-97D5-4DD8-A118-EE69F6350D18Q42670262-B36DB4C6-A2DE-4BEF-9C7D-E4A65D1CAA5DQ47136435-9F36B83B-FC88-43F4-A9DB-9C845BC4DCF6Q47672449-BD923C15-1BC1-44FC-B693-0BF0742F716EQ48634468-33813587-ACD7-4CD4-AB67-199B78E53141Q48918183-830AA324-470B-4E83-A0BF-9E1CE49F2BF1Q52670909-0B687681-E131-44A3-A964-0931C456676EQ52821559-4833C0BD-0EDB-4F80-B0B7-335F5E15D5AE
P2860
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Negative impact of bone metast ...... cinoma treated with sunitinib.
@en
Negative impact of bone metast ...... cinoma treated with sunitinib.
@nl
type
label
Negative impact of bone metast ...... cinoma treated with sunitinib.
@en
Negative impact of bone metast ...... cinoma treated with sunitinib.
@nl
prefLabel
Negative impact of bone metast ...... cinoma treated with sunitinib.
@en
Negative impact of bone metast ...... cinoma treated with sunitinib.
@nl
P2093
P2860
P356
P1433
P1476
Negative impact of bone metast ...... rcinoma treated with sunitinib
@en
P2093
B Escudier
E Barrascout
P Schöffski
P2860
P304
P356
10.1093/ANNONC/MDQ554
P577
2010-10-11T00:00:00Z